Thomas E. Goodwin Source Confirmed

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Researcher

Hendrix College

faculty

22 h-index 105 pubs 1,471 cited

Research Areas

Acute Myeloid Leukemia Research Multiple Myeloma Research and Treatments Cancer Treatment and Pharmacology Immune Response and Inflammation Pharmacological Effects and Toxicity Studies Diet and metabolism studies Cancer-related molecular mechanisms research

Links

Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Thomas E. Goodwin's research focuses on the pharmacological effects of novel dihydroorotate dehydrogenase (DHODH) inhibitors, particularly in the context of hematological malignancies. His work investigates the therapeutic potential of these compounds as monotherapies and in combination with other targeted treatments, such as CD47 blockade.

Recent publications detail the efficacy of Hosu-53, a potent DHODH inhibitor, in preclinical models of acute myeloid leukemia (AML) and multiple myeloma. Goodwin's research also explores the impact of DHODH inhibition on T cell metabolism, examining its role in modulating graft-versus-host disease (GvHD) while preserving graft-versus-leukemia (GvL) responses. His publications extend to the investigation of pyrimidine synthesis inhibition as a therapeutic strategy for small cell lung cancer.

Goodwin has a publication record of 105 works and an h-index of 22, with over 1,400 citations. He leads a research group and has collaborated with researchers from Hendrix College.

Metrics

h-index: 22
Publications: 105
Citations: 1,471

Selected Publications

Abstract 6902: Promising therapeutic effects of pyrimidine synthesis inhibition by a novel dihydroorotate dehydrogenase inhibitor in small cell lung cancer (2025) DOI
DHODH inhibition alters T cell metabolism limiting acute graft-versus-host disease while retaining graft-versus-leukemia response (2025) DOI
DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL. (2025) DOI
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia (2024) DOI
The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy (2023) DOI
Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia (2022) DOI
Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy (2022) DOI
A pachyderm perfume: odour encodes identity and group membership in African elephants (2022) DOI